Medication info
Rivaroxaban 4/160 mg

Rivaroxaban 4/160 mg

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium Hydrate›4mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
White oval film-coated tablet
Packaging
30 tablets (6 tablets/PTP x 5)
Approval status
Active

MFDS item code 201500964 · Approved 2015.02.25 · Insurance code 644913930

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, pitavastatin calcium and valsartan. Take this medicine once daily after breakfast. As aminotransferase levels may increase during treatment with this medicine, liver function tests should be performed before and during treatment. Perform liver function tests at least once within 12 weeks from the start of treatment and regularly thereafter (e.g., once every 6 months). Exercise particular caution in patients with elevated serum aminotransferase levels and perform liver function tests promptly and frequently. Pitavastatin calcium Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. The usual initial dose for adults is 1~2 mg of pitavastatin calcium once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4 mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response. The therapeutic effect of this medicine is maintained with continued use. Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is given concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose is then increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose, twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. For patients taking pitavastatin calcium and valsartan concomitantly, this medicine (a combination product containing the same amounts of each active ingredient) may be substituted for convenience.
Child dose
1. Essential hypertension: 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; reduction of the risk of death after myocardial infarction

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated apo-B protein
  • elevated triglycerides
  • essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is prescribed only for patients who need to use both Pitavastatin Calcium and Valsartan. Pitavastatin Calcium helps to improve cholesterol levels in patients with hypercholesterolemia and mixed dyslipidemia. It specifically lowers total cholesterol, bad LDL cholesterol, apo-B protein, and triglycerides, while increasing good HDL cholesterol levels. Valsartan is used for the treatment of essential hypertension and is also effective in heart failure patients who show intolerance to ACE inhibitors. Additionally, it helps to reduce the risk of death in patients with decreased left ventricular function following myocardial infarction. By using these two medications together, blood pressure and cardiovascular health, as well as cholesterol management can be effectively improved.

How to take

Adult dose

This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, pitavastatin calcium and valsartan. Take this medicine once daily after breakfast. As aminotransferase levels may increase during treatment with this medicine, liver function tests should be performed before and during treatment. Perform liver function tests at least once within 12 weeks from the start of treatment and regularly thereafter (e.g., once every 6 months). Exercise particular caution in patients with elevated serum aminotransferase levels and perform liver function tests promptly and frequently. Pitavastatin calcium Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine. The usual initial dose for adults is 1~2 mg of pitavastatin calcium once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased to a maximum of 4 mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response. The therapeutic effect of this medicine is maintained with continued use. Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years or older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When a diuretic is given concomitantly, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose is then increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose, twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. For patients taking pitavastatin calcium and valsartan concomitantly, this medicine (a combination product containing the same amounts of each active ingredient) may be substituted for convenience.

Child dose

1. Essential hypertension: 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to a fetus and newborn if taken during pregnancy; therefore, if pregnancy is confirmed, use should be stopped immediately. It should not be used in women who are allergic to this medication or its components, or who are pregnant or breastfeeding, or in patients with severe liver dysfunction or severe kidney impairment, or patients with certain genetic diseases. Caution should be exercised when prescribing to the elderly, patients with hyperkalemia, patients with a history of liver disorders, and patients with heart disease, as blood pressure may drop rapidly. Side effects such as muscle pain, weakness, dyspepsia, headache, and dizziness may occur during the use of this medication; if symptoms are severe or persistent, consultation with a doctor is necessary. Regular liver and kidney function tests should be conducted; if abnormal signs are detected, use should be stopped immediately and healthcare personnel notified. Particularly, if muscle-related symptoms or abnormalities in blood tests appear, serious conditions such as rhabdomyolysis should be suspected and monitored closely. When taking this medication with other drugs, interactions may occur, so consultation with a doctor or pharmacist is essential; it is safer not to combine it with certain medications. The safety of this medication has not been established in children; therefore, it should not be used in children, and the elderly should start with a low dose and take it carefully. In the case of overdose, severe symptoms such as hypotension and decreased consciousness can occur, so immediate medical attention should be sought for appropriate treatment. For storage, keep it out of reach of children and do not transfer to another container.

Side effects

Headache, dyspepsia, nausea, increased serum AST, chest discomfort, increased sweating, dizziness, abdominal pain, rash, lethargy, paralysis, itching, increased γ-GT, elevated plasma creatine phosphokinase levels, increased serum ALT, increased serum AST, rhabdomyolysis, myopathy, liver dysfunction, jaundice, thrombocytopenia, urticaria, erythema, angioedema, elevated bilirubin, increased cholinesterase, rigidity, drowsiness, insomnia, heaviness of head, dry mouth, abdominal bloating, constipation, stomatitis, vomiting, loss of appetite, glossitis, thrombocytopenia, granulocytopenia, leukopenia, eosinophilia, leukocytosis, elevated globulin, anemia, increased urinary frequency, elevated BUN, increased serum creatinine, decreased aldosterone, increased aldosterone, elevated adrenocorticotropic hormone, increased cortisol, decreased testosterone, muscle cramps, elevated CPK, myalgia, weakness, palpitations, fatigue, skin pain, burning sensation, arthralgia, edema, blurred vision, photophobia, hearing loss, hematuria, elevated uric acid levels, increased serum potassium and phosphorus, taste disturbances, lethargy, positive antinuclear antibodies, sleep disorders, memory loss, depression, interstitial lung disease, sexual dysfunction, diabetes mellitus, immune-mediated necrotizing myopathy, severe muscle weakness, ocular myasthenia, hypochromic anemia, facial edema, skin tingling, insomnia, loss of appetite, elevated blood pressure, asthenia, dry mouth, diarrhea, increased γ-GT, increased LDH, increased ALP, urticaria, thrombocytopenia, increased serum creatinine, elevated BUN, tinnitus, hypertonia, decreased motor function, confusion, chest pain, erythema, vasculitis, hepatitis, renal failure, shock, syncope, loss of consciousness, vesicular dermatitis, intestinal vascular edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not let in light. It is also advisable to store it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White oval film-coated tablet

Package unit

30 tablets (6 tablets/PTP x 5)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.